SLC28A3 rs7853758 as a new biomarker of tacrolimus elimination and new-onset hypertension in Chinese liver transplantation patients
SLC28A3 rs7853758 as a new biomarker of tacrolimus elimination and new-onset hypertension in Chinese liver transplantation patients
复制标题
SLC28A3 rs7853758作为中国肝移植患者他克莫司消除和新发高血压的新生物标志物
DOI：
10.2217/bmm-2017-0128
复制
发表时间：
2017-08-01
影响因子：
2.2
通讯作者：
Fan, Junwei
中科院分区：
文献类型：
--
作者：
Liu, Yuan;Zhang, Tao;Fan, Junwei
目的：SLC28A3对肝移植术后他克莫司处置和新发高血压（NOHP）的影响尚不清楚。方法与结果：来自中国肝移植注册数据库的两个队列共169例患者被纳入研究。受体SLC28A3中Rs7853758可预测两组他克莫司药代动力学。供体CYP3A5 rs776746和受体CYP3A4 rs2242480模型可以预测第1周时他克莫司的代谢，供体CYP3A5 rs776746、受体CYP3A4 rs2242480、受体SLC28A3 rs7853758和血红蛋白模型可以预测第2、3、4周时他克莫司的处置。此外，受体SLC28A3 rs7853758是LT后NOHP发生的新危险因素。结论：SLC28A3受体rs7853758与他克莫司药代动力学及中国LT患者NOHP发生风险相关。
Aim: The effect of SLC28A3 on tacrolimus disposition and new-onset hypertension (NOHP) after liver transplantation (LT) remains unclear. Methodology & results: A total of 169 patients in two cohorts from the China Liver Transplant Registry database were included. Rs7853758 in recipients' SLC28A3 could predict tacrolimus pharmacokinetics in two sets. The model of donors' CYP3A5 rs776746 and recipients' CYP3A4 rs2242480 could predict tacrolimus metabolism at week 1 and the model of donors' CYP3A5 rs776746, recipients' CYP3A4 rs2242480, recipients' SLC28A3 rs7853758 and hemoglobin could predict tacrolimus disposition at weeks 2, 3 and 4. Besides, recipients' SLC28A3 rs7853758 was a new risk factor of NOHP after LT. Conclusion: Rs7853758 in recipients' SLC28A3 has a correlation with tacrolimus pharmacokinetics and the risk of NOHP in Chinese LT patients.